Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01177735 · FLOW

Participant flow

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma · Source last updated 2021-04-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Pomalidomide: Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
    id
    FG000
    title
    Pomalidomide
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        71
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        71
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Pomalidomide: Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
    id
    FG000
    title
    Pomalidomide
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        71
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        71
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice